Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Unique Characteristics of Classical Hodgkin Lymphoma in Patients with Cutaneous T-Cell Lymphoma

Lauren E. Strelec, BA, Erin Haley, MD, Ellen J. Kim, MD, Alain H. Rook, MD, Nirav N. Shah, MD, Anthony R. Mato, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2015) 126 (23): 5003.

https://doi.org/10.1182/blood.V126.23.5003.5003

Published: 2015

Journal Articles

Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).

Vikram R Paralkar, MD, Sunita Dwivedy Nasta, MD, Kelly Morrissey, MD, Jacqueline Smith, MSN, CRNP, Pavel Vassilev, BS, Mary Ellen Martin, MD, Steven C Goldstein, MD, Alison Loren, MD, MPH, Alain H Rook, MD, Ellen J Kim, MD, David L Porter, MD

Blood (2010) 116 (21): 4574.

https://doi.org/10.1182/blood.V116.21.4574.4574

Published: 2010

Journal Articles

Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.

Youn H Kim, MD, Marie-France Demierre, MD, Ellen J Kim, MD, Alain H Rook, MD, Adam Lerner, MD, Madeleine Duvic, MD, Sunil Reddy, MD, Tadeusz Robak, MD, PhD, Jürgen C Becker, MD, Alexey Samtsov, MD, William McCulloch, MB, FRCP, Sean Whittaker, MD, FRCP

Blood (2009) 114 (22): 2683.

https://doi.org/10.1182/blood.V114.22.2683.2683

Published: 2009

Journal Articles

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.

Sean Whittaker, MD, FRCP, Ellen J Kim, MD, Miles Prince, Marie France Demierre, MD, Cynthia Giver, Sagar Lonial, MD, Richard Piekarz, MD, PhD, Youn H Kim, MD, Jean Nichols, PhD, Darrell Nix, Ph.D., Susan Bates, MD

Blood (2009) 114 (22): 3701.

https://doi.org/10.1182/blood.V114.22.3701.3701

Published: 2009

Journal Articles

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

Youn Kim, MD, Sean Whittaker, MD, FRCP, Marie France Demierre, MD, Alain H Rook, MD, Adam Lerner, MD, Madeleine Duvic, MD, Sunil Reddy, MD, Ellen J Kim, MD, Tadeusz Robak, MD, Jürgen C Becker, MD, Alexey Samtsov, MD, William McCulloch, MB, FRCP, Archibald G Prentice, MBChB, FRCP, FRCPath

Blood (2008) 112 (11): 263.

https://doi.org/10.1182/blood.V112.11.263.263

Published: 2008

Journal Articles

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

Youn H. Kim, MD, Sunil Reddy, MD, Ellen J. Kim, MD, Alain H. Rook, MD, Adam Lerner, MD, Mariefrance Demierre, MD, Madeleine Duvic, MD, Sean Whittaker, MD, FRCP, Tadeusz Robak, MD, Jurgen C. Becker, MD, William McCulloch, MB, FRCP, Archibald G. Prentice, MB, FRCP, FRCPath, on behalf of All Investigators

Blood (2007) 110 (11): 123.

https://doi.org/10.1182/blood.V110.11.123.123

Published: 2007

NARROW

Unique Characteristics of Classical Hodgkin Lymphoma in Patients with Cutaneous T-Cell Lymphoma

Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).

Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

Email alerts

ASH Publications

American Society of Hematology

Unique Characteristics of Classical Hodgkin Lymphoma in Patients with Cutaneous T-Cell Lymphoma

Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).

Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only